No Image

New tentative approval for Teva Pharms drug eltrombopag

November 26, 2022 AutoBot 0

[![eltrombopag structure](https://www.DrugPatentWatch.com/img/drug-structure/eltrombopag.png)](//www.DrugPatentWatch.com/p/preview/generic-api/eltrombopag?utm_medium=dpw_wp_blog&utm_campaign=dpw_wp_blog&utm_source=dpw_wp_blog) Eltrombopag is the generic ingredient in two branded drugs marketed by Novartis and is included in two NDAs. There are eight patents protecting […]

No Image

New tentative approval for Amneal Pharms drug saxagliptin

November 26, 2022 AutoBot 0

[![saxagliptin structure](https://www.DrugPatentWatch.com/img/drug-structure/saxagliptin.png)](//www.DrugPatentWatch.com/p/preview/generic-api/saxagliptin?utm_medium=dpw_wp_blog&utm_campaign=dpw_wp_blog&utm_source=dpw_wp_blog) Saxagliptin is the generic ingredient in one branded drug marketed by Astrazeneca Ab and is included in one NDA. There are two patents […]

No Image

Guidance Webinar Series

November 25, 2022 AutoBot 0

FDA’s Guidance Webinar series aims to foster collaboration and transparency in the development of guidance documents through direct outreach to affected stakeholders.

No Image

New tentative approval for Amneal Pharms drug saxagliptin

November 25, 2022 AutoBot 0

[![saxagliptin structure](https://www.DrugPatentWatch.com/img/drug-structure/saxagliptin.png)](//www.DrugPatentWatch.com/p/preview/generic-api/saxagliptin?utm_medium=dpw_wp_blog&utm_campaign=dpw_wp_blog&utm_source=dpw_wp_blog) Saxagliptin is the generic ingredient in one branded drug marketed by Astrazeneca Ab and is included in one NDA. There are two patents […]

No Image

New tentative approval for Teva Pharms drug eltrombopag

November 25, 2022 AutoBot 0

[![eltrombopag structure](https://www.DrugPatentWatch.com/img/drug-structure/eltrombopag.png)](//www.DrugPatentWatch.com/p/preview/generic-api/eltrombopag?utm_medium=dpw_wp_blog&utm_campaign=dpw_wp_blog&utm_source=dpw_wp_blog) Eltrombopag is the generic ingredient in two branded drugs marketed by Novartis and is included in two NDAs. There are eight patents protecting […]

No Image

New tentative approval for Teva Pharms drug eltrombopag

November 24, 2022 AutoBot 0

[![eltrombopag structure](https://www.DrugPatentWatch.com/img/drug-structure/eltrombopag.png)](//www.DrugPatentWatch.com/p/preview/generic-api/eltrombopag?utm_medium=dpw_wp_blog&utm_campaign=dpw_wp_blog&utm_source=dpw_wp_blog) Eltrombopag is the generic ingredient in two branded drugs marketed by Novartis and is included in two NDAs. There are eight patents protecting […]

No Image

New tentative approval for Amneal Pharms drug saxagliptin

November 24, 2022 AutoBot 0

[![saxagliptin structure](https://www.DrugPatentWatch.com/img/drug-structure/saxagliptin.png)](//www.DrugPatentWatch.com/p/preview/generic-api/saxagliptin?utm_medium=dpw_wp_blog&utm_campaign=dpw_wp_blog&utm_source=dpw_wp_blog) Saxagliptin is the generic ingredient in one branded drug marketed by Astrazeneca Ab and is included in one NDA. There are two patents […]

No Image

WHO lands on new name for monkeypox

November 23, 2022 AutoBot 0

The World Health Organization will rename monkeypox “MPOX” in an effort to destigmatize the virus amid growing pressure from senior Biden administration officials, Politico reported […]

No Image

Hospital CEO exits slow

November 23, 2022 AutoBot 0

Eighty-five hospital CEOs exited their roles in the first 10 months of this year, down 10.5 percent from the 95 chiefs who stepped down from […]

America, the intolerant

November 23, 2022 AutoBot 0

BY ANISH KOKA Historically, the great tension between liberty and authority was between government as embodied by the ruling class and its subjects.  Marauding barbarians […]

No Image

New tentative approval for Teva Pharms drug eltrombopag

November 23, 2022 AutoBot 0

[![eltrombopag structure](https://www.DrugPatentWatch.com/img/drug-structure/eltrombopag.png)](//www.DrugPatentWatch.com/p/preview/generic-api/eltrombopag?utm_medium=dpw_wp_blog&utm_campaign=dpw_wp_blog&utm_source=dpw_wp_blog) Eltrombopag is the generic ingredient in two branded drugs marketed by Novartis and is included in two NDAs. There are eight patents protecting […]

No Image

New tentative approval for Amneal Pharms drug saxagliptin

November 23, 2022 AutoBot 0

[![saxagliptin structure](https://www.DrugPatentWatch.com/img/drug-structure/saxagliptin.png)](//www.DrugPatentWatch.com/p/preview/generic-api/saxagliptin?utm_medium=dpw_wp_blog&utm_campaign=dpw_wp_blog&utm_source=dpw_wp_blog) Saxagliptin is the generic ingredient in one branded drug marketed by Astrazeneca Ab and is included in one NDA. There are two patents […]